BOT - Anything but charting, page-6837

Thanks for sharing Brune. Interesting though that just recently the market couldn't get enough of BOT at 13c with the Cap Raising being oversubscribed and $13m raised. I doubt these institutions were looking at only a 4c profit. That said, I do think the market in general and the likes of Petra perhaps are underestimating BOT. It would be interesting to read a more thorough analysis of theirs and see what they think about the confirmed Japanese sales and how they think these apply to the US and greater world market - particularly with this being the only new drug for axillary hyperhidrosis users in decades, and one which outperforms all others also.